Diagnostics
Sudden unexpected death in epilepsy (SUDEP) occurs in approximately 1/1000 people with epilepsy and is poorly understood
Myriad Genetics, Inc. today announced that that its BRACAnalysis CDx® test accurately identified patients with newly-diagnosed, advanced-stage, BRCA-mutated (BRCAm) ovarian cancer who may benefit from treatment with Lynparza® (olaparib).
Agreement demonstrates growing use of OncoDNA solutions across Europe
Glycotest Inc., Inc. announced today the close of a Series A funding round of $10 million from Shanghai Fosun Pharmaceutical Co., Ltd.
What do you wish someone would’ve told you at the beginning of your career? Most people reflect on their career development and think, ‘If only I knew then what I know now, I’d be farther along.’
Company announces patented blood-based diagnostic test expanding to other autoimmune diseases as well as cancer
Myriad Genetics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® to be used by healthcare professionals to identify patients with HER2-negative metastatic breast cancer (mBC) who have a germline BRCA mutation and are eligible for treatment with Pfizer’s PARP (poly ADP ribose polymerase) inhibitor, TALZENNA® (talazoparib).
DNAe was named ‘Best Diagnostic Medtech Company’ at the 2018 OBN Awards.
Sysmex Inostics is pleased to announce publication of a study in the Journal of Molecular Oncology highlighting the important clinical value of blood-based ctDNA mutation testing to complement standard-of-care management of patients with advanced melanoma.
TIME Magazine came out with a list of the 50 most influential people in healthcare, dubbed The Health Care 50. A look through the list shows just how many ties and connections—as well as influence—this group has on the biopharma industry.
PRESS RELEASES